Frequent loss of NISCH promotes tumor proliferation and invasion in ovarian cancer via inhibiting the FAK signal pathway

Molecular Cancer Therapeutics

Volumn 14, Issue 5, 2015, Pages 1202-1212

  Li, Jing ^a,b   He, Xiaoying ^c   Dong, Ruofan ^d   Wang, Yuan ^d   Yu, Jinjin ^d   Qiu, Haifeng ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b Open Laboratory of Key Discipline of Clinical Medical Sciences   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d JIANGNAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; IMIDAZOLINE RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NISCHARIN; PF 562271; UNCLASSIFIED DRUG; AZACITIDINE; DECITABINE; FOCAL ADHESION KINASE 1; NISCH PROTEIN, HUMAN; PTK2 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL INVASION; CELL PROLIFERATION; COLONY FORMATION; COLONY FORMING UNIT; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; FEMALE; FOLLOW UP; GENE SILENCING; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; METASTASIS; MIDDLE AGED; MOUSE; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL; TUMOR INVASION; UPREGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; CANCER TRANSPLANTATION; DRUG EFFECTS; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

AZACITIDINE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; DOWN-REGULATION; FEMALE; FOCAL ADHESION KINASE 1; HUMANS; IMIDAZOLINE RECEPTORS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LOSS OF HETEROZYGOSITY; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION;

EID: 84942107493     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0911     Document Type: Article

References (23)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
3. Stat Bite. Ovarian cancer, five-year stage-specific relative survival rates (2004-2008). J Natl Cancer Inst 2011;103:1287.
4. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011;11:719-25.
5. Montopoli M, Bellanda M, Lonardoni F, Ragazzi E, Dorigo P, FroldiG, et al. "Metabolic reprogramming" in ovarian cancer cells resistant to cisplatin. Curr Cancer Drug Targets 2011;11:226-35.
6. Bookman MA. First-line chemotherapy in epithelial ovarian cancer. Clin Obstet Gynecol 2012;55:96-113.
7. Lorusso D, Pietragalla A, Mainenti S, Di Legge A, Amadio G, Scambia G. Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs 2010;15:635-52.
8. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet 2014;384:1376-88.
9. Alahari SK, Lee JW, Juliano RL. Nischarin, a novel protein that interacts with the integrin alpha5 subunit and inhibits cell migration. J Cell Biol 2000;151:1141-54.
10. Alahari SK. Nischarin inhibits Rac induced migration and invasion of epithelial cells by affecting signaling cascades involving PAK. Exp Cell Res 2003;288:415-24.
11. Alahari SK, Reddig PJ, Juliano RL. The integrin-binding protein Nischarin regulates cell migration by inhibiting PAK. EMBO J 2004;23:2777-88.
12. Ding Y, Milosavljevic T, Alahari SK. Nischarin inhibits LIM kinase to regulate cofilin phosphorylation and cell invasion. Mol Cell Biol 2008;28:3742-56.
13. Jain P, Baranwal S, Dong S, Struckhoff AP, Worthylake RA, Alahari SK. Integrin-binding protein nischarin interacts with tumor suppressor liver kinase B1 (LKB1) to regulate cell migration of breast epithelial cells. J Biol Chem 2013;288:15495-509.
14. Baranwal S, Wang Y, Rathinam R, Lee J, Jin L, McGoey R, et al. Molecular characterization of the tumor-suppressive function of nischarin in breast cancer. J Natl Cancer Inst 2011;103:1513-28.
15. Solomon H, Brosh R, Buganim Y, Rotter V. Inactivation of the p53 tumor suppressor gene and activation of the Ras oncogene: cooperative events in tumorigenesis. Discov Med 2010;9:448-54.
16. Ajioka I, Dyer MA. A new model of tumor susceptibility following tumor suppressor gene inactivation. Cell Cycle 2008;7:735-40.
17. Saldana-Meyer R, Recillas-Targa F. Transcriptional and epigenetic regulation of the p53 tumor suppressor gene. Epigenetics 2011;6:1068-77.
18. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004;10:3291-300.
19. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
20. Colombo PE, Fabbro M, Theillet C, Bibeau F, Rouanet P, Ray-Coquard I. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit Rev Oncol Hematol 2014;89:207-16.
21. Ward KK, Tancioni I, Lawson C, Miller NL, Jean C, Chen XL, et al. Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression. Clin ExpMetastasis 2013;30:579-94.
22. Shah NR, Tancioni I, Ward KK, Lawson C, Chen XL, Jean C, et al. Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer. Gynecol Oncol 2014;134:104-11.
23. Tancioni I, Uryu S, Sulzmaier FJ, Shah NR, Lawson C, Miller NL, et al. FAK inhibition disrupts a beta5 integrin signaling axis controlling anchorageindependent ovarian carcinoma growth. Mol Cancer Ther 2014;13:2050-61.